Shih-Ying Wu

Shih-Ying Wu

Auto-generated profile, based on publicly available information

Shih-Ying Wu

Department of Asthma, Allergy and Respiratory Science and Randall Division of Cell and Molecular Biophysics, King's College London; the Medical Research Council and Asthma UK Centre, Allergic Mechanisms in Asthma, London; the Department of Paediatric Allergy, Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
ASAlexandra F Figueira Santos
Alexandra F Figueira Santos
Abdel DouiriAbdel Douiri
Abdel Douiri
NBNatalia Bécares
Natalia Bécares
SWShih-Ying Wu
Shih-Ying Wu
ASAlick Stephens
Alick Stephens
GLGideon Lack
Gideon Lack
Most of the peanut-sensitized children do not have clinical peanut allergy. In equivocal cases, oral food challenges (OFCs) are required. However, OFCs are laborious and not without risk; thus, a test that could accurately diagnose peanut allergy and reduce the need for OFCs is desirable. To assess the performance of basophil activation test (BAT) as a diagnostic marker for peanut allergy. Peanut-allergic (n = 43), peanut-sensitized but tolerant (n = 36) and non-peanut-sensitized nonallergic (n = 25) children underwent skin prick test (SPT) and specific IgE (sIgE) to peanut and its components. BAT was performed using flow cytometry, and its diagnostic performance was evaluated in relation to allergy versus tolerance to peanut and validated in an independent population (n = 65). BAT in peanut-allergic children showed a peanut dose-dependent upregulation of CD63 and CD203c while there was no significant response to peanut in peanut-sensitized but tolerant (P < .001) and non-peanut-sensitized nonallergic children (P < .001). BAT optimal diagnostic cutoffs showed 97% accuracy, 95% positive predictive value, and 98% negative predictive value. BAT allowed reducing the number of required OFCs by two-thirds. BAT proved particularly useful in cases in which specialists could not accurately diagnose peanut allergy with SPT and sIgE to peanut and to Arah2. Using a 2-step diagnostic approach in which BAT was performed only after equivocal SPT or Arah2-sIgE, BAT had a major effect (97% reduction) on the number of OFCs required. BAT proved to be superior to other diagnostic tests in discriminating between peanut allergy and tolerance, particularly in difficult cases, and reduced the need for OFCs.

1 December 2014 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
YCYih-Chih Chan
Yih-Chih Chan
FRFaruk Ramadani
Faruk Ramadani
ASAlexandra F Figueira Santos
Alexandra F Figueira Santos
PPPrathap Pillai
Prathap Pillai
LOLine Ohm-Laursen
Line Ohm-Laursen
HGHannah J. Gould
Hannah J. Gould
Naturally occurring IgE-specific IgG autoantibodies have been identified in patients with asthma and other diseases, but their spectrum of functions is poorly understood. Address the hypothesis that: (i) IgG anti-IgE autoantibodies are detectable in the serum of all subjects but elevated in asthmatic patients regardless of atopic status as compared with controls; (ii) some activate IgE-sensitized basophils; and (iii) some inhibit allergen-induced basophil activation. IgE-specific IgG autoantibodies were detected and quantified in sera using ELISA. Sera were examined for their ability to activate IgE-sensitized human blood basophils in the presence and absence of allergen using a basophil activation test, and to inhibit allergen binding to specific IgE on a rat basophilic cell line stably expressing human FcεRI. IgG autoantibodies binding to both free and FcεRI-bound IgE were detected in patients with atopic and non-atopic asthma, as well as controls. While some were able to activate IgE-sensitised basophils, others inhibited allergen-induced basophil activation, at least partly by inhibiting binding of IgE to specific allergen. Naturally occurring IgG anti-IgE autoantibodies may inhibit, as well as induce, basophil activation. They act in a manner distinct from therapeutic IgG anti-IgE antibodies such as omalizumab. They may at least partly explain why atopic subjects who make allergen-specific IgE never develop clinical symptoms, and why omalizumab therapy is of variable clinical benefit in severe atopic asthma.

1 June 2014 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
PPPrathap Pillai
Prathap Pillai
CFCailong Fang
Cailong Fang
YCYih-Chih Chan
Yih-Chih Chan
MSMohamed H. Shamji
Mohamed H. Shamji
CHClare Harper
Clare Harper
HGHannah J. Gould
Hannah J. Gould